Literature DB >> 23857040

Updates in the management of high-grade glioma.

David Bradley1, Jeremy Rees.   

Abstract

The management of high-grade glioma (HGG) has evolved significantly over the last decade. Patients are managed in a multidisciplinary team setting in order to ensure their care is guided by the most current evidenced based treatments. The outcome in patients with HGG, while still poor, has improved in terms of both survival and quality of life during illness. This review discusses a number of developments seen in the management of HGG over the last 5 years.

Entities:  

Mesh：

Year:  2013        PMID： 23857040     DOI： 10.1007/s00415-013-7032-x

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  43 in total

1.  Bevacizumab use for recurrent high-grade glioma at McGill University Hospital.

Authors:  Solmaz Sahebjam; Evgenia Garoufalis; Marie-Christine Guiot; Thierry Muanza; Rolando Del Maestro; Kevin Petrecca; Rajesh Sharma; Petr Kavan
Journal:  Can J Neurol Sci       Date:  2013-03       Impact factor: 2.104

2.  Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.

Authors:  Marc C Chamberlain; Sandra Johnston
Journal:  J Neurooncol       Date:  2008-10-25       Impact factor: 4.130

3.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

4.  A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.

Authors:  Guobin Zhang; Shengyue Huang; Zhongcheng Wang
Journal:  J Clin Neurosci       Date:  2012-10-06       Impact factor: 1.961

5.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

6.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

7.  Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.

Authors:  Ashwatha Narayana; Patrick Kelly; John Golfinos; Erik Parker; Glyn Johnson; Edmond Knopp; David Zagzag; Ingeborg Fischer; Shahzad Raza; Praveen Medabalmi; Patricia Eagan; Michael L Gruber
Journal:  J Neurosurg       Date:  2009-01       Impact factor: 5.115

8.  Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.

Authors:  Ulrik Lassen; Morten Sorensen; Tine Bernhardtsen Gaziel; Benedikte Hasselbalch; Hans Skovgaard Poulsen
Journal:  Anticancer Res       Date:  2013-04       Impact factor: 2.480

9.  Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.

Authors:  Eudocia C Quant; Andrew D Norden; Jan Drappatz; Alona Muzikansky; Lisa Doherty; Debra Lafrankie; Abigail Ciampa; Santosh Kesari; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2009-03-30       Impact factor: 12.300

10.  Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma.

Authors:  Motoo Nagane; Ryo Nishikawa; Yoshitaka Narita; Hiroyuki Kobayashi; Shingo Takano; Nobusada Shinoura; Tomokazu Aoki; Kazuhiko Sugiyama; Junichi Kuratsu; Yoshihiro Muragaki; Yutaka Sawamura; Masao Matsutani
Journal:  Jpn J Clin Oncol       Date:  2012-07-27       Impact factor: 3.019
View more
  7 in total

1.  miR-106b-5p Inhibits IRF1/IFN-β Signaling to Promote M2 Macrophage Polarization of Glioblastoma.

Authors:  Yu Shi; Bin Zhang; Jian Zhu; Wu Huang; Bin Han; Qilong Wang; Chunjian Qi; Minghai Wang; Fang Liu
Journal:  Onco Targets Ther       Date:  2020-07-30       Impact factor: 4.147

2.  Identifying the association between contrast enhancement pattern, surgical resection, and prognosis in anaplastic glioma patients.

Authors:  Yinyan Wang; Kai Wang; Jiangfei Wang; Shaowu Li; Jun Ma; Jianping Dai; Tao Jiang
Journal:  Neuroradiology       Date:  2016-01-21       Impact factor: 2.804

3.  Proinflammatory-activated glioma cells induce a switch in microglial polarization and activation status, from a predominant M2b phenotype to a mixture of M1 and M2a/B polarized cells.

Authors:  Lucia Lisi; Egidio Stigliano; Libero Lauriola; Pierluigi Navarra; Cinzia Dello Russo
Journal:  ASN Neuro       Date:  2014-05-08       Impact factor: 4.146

4.  MEX3A contributes to development and progression of glioma through regulating cell proliferation and cell migration and targeting CCL2.

Authors:  Chao Yang; Haoqiang Zhan; Yiqing Zhao; Yasong Wu; Lisha Li; Heping Wang
Journal:  Cell Death Dis       Date:  2021-01-04       Impact factor: 8.469

5.  Clinicopathological and Prognostic Significance of ABCC3 in Human Glioma.

Authors:  Dan-Dong Fang; Wei Huang; Gang Cheng; Xiao-Nan Liu; Shi-Min Liu; Bao-Sen Hou; Jian Mao; Hu Zhou
Journal:  J Oncol       Date:  2021-12-23       Impact factor: 4.375

6.  The mTOR kinase inhibitors polarize glioma-activated microglia to express a M1 phenotype.

Authors:  Lucia Lisi; Emilia Laudati; Pierluigi Navarra; Cinzia Dello Russo
Journal:  J Neuroinflammation       Date:  2014-07-23       Impact factor: 8.322

7.  Restoring the oncosuppressor activity of microRNA-34a in glioblastoma using a polyglycerol-based polyplex.

Authors:  Paula Ofek; Marcelo Calderón; Fatemeh Sheikhi Mehrabadi; Adva Krivitsky; Shiran Ferber; Galia Tiram; Noga Yerushalmi; Sharon Kredo-Russo; Rachel Grossman; Zvi Ram; Rainer Haag; Ronit Satchi-Fainaro
Journal:  Nanomedicine       Date:  2016-06-01       Impact factor: 5.307
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.